[1] Z.R. Chen WQ, Peter D. B, Siwei Z, Zeng HM , Freddie B, Cancer Statistics in China, 2015. CA CANCER J CLIN (2016).
[2] R.L. Siegel, K.D. Miller, and A. Jemal, Cancer statistics, 2019. CA Cancer J Clin.(2019) 69: 7-34.
[3] NCCN Guidelines Version 1.2019 Pancreatic Adenocarcinoma. Available from: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf.(Accessed November 8, 2018).
[4] J. Tabernero, E.G. Chiorean, J.R. Infante, S.R. Hingorani, V. Ganju, C. Weekes, W. Scheithauer, R.K. Ramanathan, D. Goldstein, D.N. Penenberg, A. Romano, S. Ferrara, and D.D. Von Hoff, Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Oncologist.(2015) 20: 143-50.
[5] V. Heinemann, D. Quietzsch, F. Gieseler, M. Gonnermann, H. Schonekas, A. Rost, H. Neuhaus, C. Haag, M. Clemens, B. Heinrich, U. Vehling-Kaiser, M. Fuchs, D. Fleckenstein, W. Gesierich, D. Uthgenannt, H. Einsele, A. Holstege, A. Hinke, A. Schalhorn, and R. Wilkowski, Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol.(2006) 24: 3946-52.
[6] V. Heinemann, S. Boeck, A. Hinke, R. Labianca, and C. Louvet, Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer.(2008) 8: 82.
[7] D.F. Conroy T, Ychou M, FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N Engl J Med.(2011) 364: 1817-1825.
[8] G.-F. Liu, G.-J. Li, and H. Zhao, Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta-Analysis. Journal of Cellular Biochemistry.(2018) 119: 511-523.
[9] R. Gupta, I. Amanam, and V. Chung, Current and future therapies for advanced pancreatic cancer. J Surg Oncol.(2017) 116: 25-34.
[10] K.S. Goonetilleke, and A.K. Siriwardena, Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. European Journal of Surgical Oncology (EJSO).(2007) 33: 266-270.
[11] X. Yan, H. Wan, X. Hao, T. Lan, W. Li, L. Xu, K. Yuan, and H. Wu, Importance of gene expression signatures in pancreatic cancer prognosis and the establishment of a prediction model. Cancer Manag Res.(2019) 11: 273-283.
[12] P. Raman, R. Maddipati, K.H. Lim, and A. Tozeren, Pancreatic cancer survival analysis defines a signature that predicts outcome. PLoS One.(2018) 13: e0201751.
[13] M. Wu, X. Li, T. Zhang, Z. Liu, and Y. Zhao, Identification of a Nine-Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival of Pancreatic Cancer. Frontiers in Oncology.(2019) 9.
[14] L. Wang, J. Shi, Y. Huang, S. Liu, J. Zhang, H. Ding, J. Yang, and Z. Chen, A six-gene prognostic model predicts overall survival in bladder cancer patients. Cancer Cell Int.(2019) 19: 229.
[15] W. Pu, X. Geng, S. Chen, L. Tan, Y. Tan, A. Wang, Z. Lu, S. Guo, X. Chen, and J. Wang, Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma. J Cancer.(2016) 7: 2280-2289.
[16] X. Zheng, N. Zhang, H.J. Wu, and H. Wu, Estimating and accounting for tumor purity in the analysis of DNA methylation data from cancer studies. Genome Biol.(2017) 18: 17.
[17] X. Yang, L. Gao, and S. Zhang, Comparative pan-cancer DNA methylation analysis reveals cancer common and specific patterns. Brief Bioinform.(2017) 18: 761-773.
[18] C. Gao, J. Zhuang, H. Li, C. Liu, C. Zhou, L. Liu, and C. Sun, Exploration of methylation-driven genes for monitoring and prognosis of patients with lung adenocarcinoma. Cancer Cell Int.(2018) 18: 194.
[19] T. Lu, D. Chen, Y. Wang, X. Sun, S. Li, S. Miao, Y. Wo, Y. Dong, X. Leng, W. Du, and W. Jiao, Identification of DNA methylation-driven genes in esophageal squamous cell carcinoma: a study based on The Cancer Genome Atlas. Cancer Cell Int.(2019) 19: 52.
[20] J. Long, P. Chen, J. Lin, Y. Bai, X. Yang, J. Bian, Y. Lin, D. Wang, X. Yang, Y. Zheng, X. Sang, and H. Zhao, DNA methylation-driven genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma. Theranostics.(2019) 9: 7251-7267.
[21] Y. Bai, C. Wei, Y. Zhong, Y. Zhang, J. Long, S. Huang, F. Xie, Y. Tian, X. Wang, and H. Zhao, Development and Validation of a Prognostic Nomogram for Gastric Cancer Based on DNA Methylation-Driven Differentially Expressed Genes. Int J Biol Sci.(2020) 16: 1153-1165.
[22] R.L. Siegel, K.D. Miller, and A. Jemal, Cancer statistics, 2018. CA Cancer J Clin.(2018) 68: 7-30.
[23] L. Huang, L. Jansen, Y. Balavarca, E. Molina-Montes, M. Babaei, L. van der Geest, V. Lemmens, L. Van Eycken, H. De Schutter, T.B. Johannesen, C.W. Fristrup, M.B. Mortensen, M. Primic-Zakelj, V. Zadnik, N. Becker, T. Hackert, M. Magi, T. Cassetti, R. Sassatelli, R. Grutzmann, S. Merkel, A.F. Goncalves, M.J. Bento, P. Hegyi, G. Lakatos, A. Szentesi, M. Moreau, T. van de Velde, A. Broeks, M. Sant, P. Minicozzi, V. Mazzaferro, F.X. Real, A. Carrato, X. Molero, M.G. Besselink, N. Malats, M.W. Buchler, P. Schrotz-King, and H. Brenner, Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Gut.(2019) 68: 130-139.
[24] F.T.S.K.R.C.F.S.B.S.R.D.D. Duranyildiz, Serum levels of LDH, CEA, and CA19‑9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine‑based chemotherapy.pdf. Cancer Chemother Pharmacol (2014) 73: 1163–1171.
[25] L. Liu, H. Xu, W. Wang, C. Wu, Y. Chen, J. Yang, P. Cen, J. Xu, C. Liu, J. Long, S. Guha, D. Fu, Q. Ni, A. Jatoi, S. Chari, A.L. McCleary-Wheeler, M.E. Fernandez-Zapico, M. Li, and X. Yu, A preoperative serum signature of CEA+/CA125+/CA19-9 >/= 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. Int J Cancer.(2015) 136: 2216-27.
[26] D.S. Swords, M.A. Firpo, C.L. Scaife, and S.J. Mulvihill, Biomarkers in pancreatic adenocarcinoma: current perspectives. Onco Targets Ther.(2016) 9: 7459-7467.
[27] T. Hamada, Y. Nakai, H. Yasunaga, H. Isayama, H. Matsui, N. Takahara, T. Sasaki, K. Takagi, T. Watanabe, H. Yagioka, H. Kogure, T. Arizumi, N. Yamamoto, Y. Ito, K. Hirano, T. Tsujino, M. Tada, and K. Koike, Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy. Br J Cancer.(2014) 110: 1943-9.
[28] S.H. Choi, S.W. Park, and J. Seong, A nomogram for predicting survival of patients with locally advanced pancreatic cancer treated with chemoradiotherapy. Radiother Oncol.(2018) 129: 340-346.
[29] H. Shen, and P.W. Laird, Interplay between the cancer genome and epigenome. Cell.(2013) 153: 38-55.
[30] C.C. Liu, D.L. Cai, F. Sun, Z.H. Wu, B. Yue, S.L. Zhao, X.S. Wu, M. Zhang, X.W. Zhu, Z.H. Peng, and D.W. Yan, FERMT1 mediates epithelial-mesenchymal transition to promote colon cancer metastasis via modulation of beta-catenin transcriptional activity. Oncogene.(2017) 36: 1779-1792.
[31] S. Roche, F. O'Neill, J. Murphy, N. Swan, J. Meiller, N.T. Conlon, J. Geoghegan, K. Conlon, R. McDermott, R. Rahman, S. Toomey, N.L. Straubinger, R.M. Straubinger, R. O'Connor, G. McVey, M. Moriarty, and M. Clynes, Establishment and Characterisation by Expression Microarray of Patient-Derived Xenograft Panel of Human Pancreatic Adenocarcinoma Patients. Int J Mol Sci.(2020) 21.
[32] X.D. Chang, Y.J. Gu, S. Dai, X.R. Chen, C.L. Zhang, H.S. Zhao, and Q.H. Song, Novel mutations in the lipase H gene lead to secretion defects of LIPH in Chinese patients with autosomal recessive woolly hair/hypotrichosis (ARWH/HT). Mutagenesis.(2017) 32: 599-606.
[33] W. Jin, U.C. Broedl, H. Monajemi, J.M. Glick, and D.J. Rader, Lipase H, a new member of the triglyceride lipase family synthesized by the intestine. Genomics.(2002) 80: 268-73.
[34] H. Lin, Z. Yin, X.Y. Yu, N. Lin, Y. Lin, J. Chen, Y.Z. Chen, K.P. Lu, and H.K. Liu, Variants -250G/A and -514C/T in the LIPC gene are associated with hypertensive disorders of pregnancy in Chinese women. Genet Mol Res.(2014) 13: 6126-34.
[35] Y. Zhang, X. Zhu, X. Qiao, X. Gu, J. Xue, Y. Han, L. Sun, M. Cui, and C. Liu, LIPH promotes metastasis by enriching stem‐like cells in triple‐negative breast cancer. Journal of Cellular and Molecular Medicine.(2020).
[36] M. Cui, H. Jin, X. Shi, G. Qu, L. Liu, X. Ding, Y. Wang, and C. Niu, Lipase member H is a novel secreted protein associated with a poor prognosis for breast cancer patients. Tumor Biology.(2014) 35: 11461-11465.
[37] Q.P. Susanne Stemmler, Elisabeth Petrasch-Parwez, Joerg T Epplen, Sabine Hoffjan, Association of variation in the LAMA3 gene, encoding the alpha-chain of laminin 5, with atopic dermatitis in a German case–control cohort. BMC Dermatology (2014) 14.
[38] L. Tang, P. Wang, Q. Wang, and L. Zhong, Correlation of LAMA3 with onset and prognosis of ovarian cancer. Oncol Lett.(2019) 18: 2813-2818.
[39] Z.L. Chengkun Yang, Xianmin Zeng, Qiongyuan Wu, Xiwen Liao, Xiangkun Wang, Evaluation of the diagnostic ability of laminin gene family for pancreatic ductal adenocarcinoma. Aging (Albany NY).(2019 ) 11: 3679–3703.
[40] Z. Pan, L. Li, Q. Fang, Y. Zhang, X. Hu, Y. Qian, and P. Huang, Analysis of dynamic molecular networks for pancreatic ductal adenocarcinoma progression. Cancer Cell Int.(2018) 18: 214.
[41] D. Karthik, and S. Ravikumar, Characterization of the brain proteome of rats with diabetes mellitus through two-dimensional electrophoresis and mass spectrometry. Brain Res.(2011) 1371: 171-9.
[42] W. Zhang, S. Shang, Y. Yang, P. Lu, T. Wang, X. Cui, and X. Tang, Identification of DNA methylation‑driven genes by integrative analysis of DNA methylation and transcriptome data in pancreatic adenocarcinoma. Experimental and Therapeutic Medicine.(2020).
[43] J.J.S.a.G. POWI, Cytosolic NAD(P)H (quinone-acceptor)oxidoreductase in human normal and tumor tissue effects of cigarette smoking and alcohol. Int. J. Cancer.(1990) 45: 403-409.
[44] M. Ji, A. Jin, J. Sun, X. Cui, Y. Yang, L. Chen, and Z. Lin, Clinicopathological implications of NQO1 overexpression in the prognosis of pancreatic adenocarcinoma. Oncol Lett.(2017) 13: 2996-3002.
[45] A.M. Lewis, M. Ough, M.M. Hinkhouse, M.S. Tsao, L.W. Oberley, and J.J. Cullen, Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancer. Mol Carcinog.(2005) 43: 215-24.
[46] A.M. Isabelle Chr´etien, Mich`ele Courtet, Kaisa Katevuo, CTX, a Xenopus thymocyte receptor, defines a molecular family conserved throughout vertebrates. Eur. J. Immunol.(1998) 28: 4094–4104.
[47] H. Yan, J. Qu, W. Cao, Y. Liu, G. Zheng, E. Zhang, and Z. Cai, Identification of prognostic genes in the acute myeloid leukemia immune microenvironment based on TCGA data analysis. Cancer Immunol Immunother.(2019) 68: 1971-1978.